Last reviewed · How we verify
NCT07513233: HEAL
Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL)
Phase 1 trial testing Anisodine Hydrobromide in Acute Ischemic Stroke in 92 participants. Not yet recruiting.
1 August 2026
Quick facts
| Lead sponsor | Capital Medical University |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 92 |
| Start date | 15 April 2026 |
| Primary completion | 1 August 2026 |
| Estimated completion | 30 October 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Anisodine Hydrobromide — full drug profile →
Conditions studied
- Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →
Sponsor
Capital Medical University
Who can join
Adults 18 to 80, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an investigator-initiated Phase 1b clinical trial employing an open-label, non-randomized, dose-escalation design. The primary objective is to evaluate the safety and tolerability of the investigational intervention and to determine the recommended dose for subsequent clinical studies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07513233
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anisodine Hydrobromide
Trials testing the same drug.
- NCT05416476 — Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine · Phase 3 · unknown
Other recruiting trials for Acute Ischemic Stroke
Currently open trials in the same condition.
- NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
- NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
- NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
- NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
- NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting
Other Capital Medical University trials
Trials by the same sponsor.
- NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
- NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting
- NCT07472114 — Effect of tNGS on CAP Patients With Initial Treatment Failure · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07513233 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07513233.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing